{
  "id": "5d38462b7bc3fee31f000012",
  "type": "yesno",
  "question": "Does metformin alleviate atherosclerosis?",
  "ideal_answer": "Yes. Metformin has been shown to decrease frequency of atherosclerosis-associated adverse effects in statin-intolerant patients and to slow the pathogenesis of type 2 diabetes mellitus.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
    "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
    "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
    "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
    "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
    "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
    "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
    "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
    "http://www.ncbi.nlm.nih.gov/pubmed/27737949"
  ],
  "snippets": [
    {
      "text": "Metformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti-inflammatory and anti-atherosclerotic properties. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "pleiotropic benefits of metformin in attenuation of atherosclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pleiotropic effects of metformin ameliorate atherosclerosis and vascular senescence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Metformin attenuated Ang-II-induced atheromatous plaque formation and aortic aneurysm in ApoE(-/-) mice partly by reducing monocyte infiltration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Metformin, an anti-diabetic drug, was reported to possess anti-atherosclerotic effects. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " In cultured macrophages, co-treatment with metformin and atorvastatin promoted cholesterol efflux and up-regulated expression of ATP-binding cassette transporters A1 and G1. Taken together, our results suggest that atorvastatin/metformin combination therapy may achieve additional anti-atherosclerotic benefits likely through increasing cholesterol efflux in macrophages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "metformin abated the progression of diabetes-accelerated atherosclerosis by inhibiting mitochondrial fission in endothelial cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "metformin attenuated the development of atherosclerosis by reducing Drp1-mediated mitochondrial fission in an AMPK-dependent manner. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "metformin's effects on lipids and atherosclerotic vascular disease and/or provide insights into the drug's mechanisms of action on the heart and vasculature.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several recently completed randomized clinical trials have reported effects of metformin on surrogate measures of atherosclerotic vascular disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}